Roche Holding Ag Stock News

DUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The market is expected to reach $25.95 billion in 2025 at a CAGR of 4%. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, B

The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the RSV Diagnostics industry. This wide-ranging market research report acts as a backbone for the success of business

The Global Tissue Testing Market Report 2021 to 2027 could be a fundamental examination of the global analysis. Trending innovation, advertise drivers, sectional declination, analysis measurements, advertise forecasts, manufacturers, and hardware merchants are all included within the substance. The report

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60% complete response rate. The data comes f

The Global Genechip Scanner Market 2021-2027 research study examines industry growth, market size, top manufacturers, future opportunities, development trends, and estimates for the Genechip Scanner Markets initial and future estimates. Key company profiles with business revenue, CAGR status, future predictions,

Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcarePreparing DNA for sequencing libraries

People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to missed or delayed diagnoses of bleeding episodes and

Basel, 13 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the AVENIO Edge System, a core component of Roches strategy to advance sequencing technologies. Built on best-in-class foundational capabilities to deliver a fully-automated, integrated sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment and quantification steps that deliver integrated, end-to-end control with reliable, consistent high-quality results. Roche is committed to developing diagnostic solutions with the goal of providing the healthcare community with faster and more accurate medical information to predict risk and detect disease, said Thomas Schinecker, CEO Roche Diagnostics. We are pleased to offer next-generation sequencing laboratories and translational researchers the new automated AVENIO Edge System that aims to drastically reduce human error and help ensure fast, reliable and accurate results. Next-generation sequencing samples are precious.

Basel, 13 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from an interim analysis of the phase III HAVEN 6 study, which show Hemlibra® (emicizumab) demonstrated a favourable safety profile and effective bleed control in people with moderate or mild haemophilia A without factor VIII inhibitors. 3 The data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition as an oral presentation on 12 December 2021.

An off-the-shelf bispecific antibody developed by Roche induced high and durable response rates in patients with a slow-growing type of lymphoma.

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that it will present new pivotal data on its CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition from December 11-14, 2021. According to the company, emerging data continue to show the promising

Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with follicular lymphoma who have received two or more prior therapies1New e

Global Blood Testing Services Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of

Related Stocks: ROG , DOV , 1COV , 2587 , RIO , GALP , CBA , CS , O39 , 6752 , 0N4T , 5020 , AZN , DGE , 7203 , VEA , 2317 , NDASE , U11 , D05 , CAT , TRYG , MRW ,

Roche Holdings AG (OTC: RHHBY ) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus Tecentriq as an initial treatment for PD-L1-positive metastatic non-small cell lung cancer. After 2.5 years median follow-up, tiragolumab/Tecentriq combo regime continued to Full story available on Benzinga.com